{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:20:45Z","timestamp":1795126845471,"version":"4.10.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA224070"],"award-info":[{"award-number":["CA224070"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There are currently no effective targeted therapies for BRAF-mutant metastatic melanoma patients with acquired resistance to approved BRAF and MEK inhibitors (BRAFi and MEKi), and very few ongoing clinical trials. Anti-apoptotic BCL2 family proteins promote de novo resistance to several therapies, including single-agent BRAFi in BRAF-mutant melanomas. In this study, in vivo testing of a large collection of patient-derived xenograft (PDX) models from melanoma patients with acquired resistance to BRAFi or BRAFi+MEKi shows that combining BCL2 inhibitors (BCL2i; navitoclax or venetoclax) with BRAFi+MEKi induces tumor regressions in a subset of these PDXs. High basal BCL2 predicts response whereas high basal MCL1 predicts resistance to this strategy. MCL1 overexpression studies functionally validate its role in resistance. Further, combining BRAFi+MEKi with an MCL1 inhibitor (MCL1i) counteracts resistance and interestingly decreases MCL1i-associated markers of cardiotoxicity. Together these studies identify potential personalized strategies to improve outcomes in this challenging patient population.<\/jats:p>","DOI":"10.1038\/s41467-026-74691-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:33:35Z","timestamp":1782495215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3118-0011","authenticated-orcid":false,"given":"Y. N.","family":"Vashisht Gopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaley","family":"Loftin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Knighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-7645","authenticated-orcid":false,"given":"Debora","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-7485","authenticated-orcid":false,"given":"Courtney","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Shamsutdinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehboob","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7775-6585","authenticated-orcid":false,"given":"Toshitha","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fontenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6272-5467","authenticated-orcid":false,"given":"Michael S.","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalida","family":"Wani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-6484","authenticated-orcid":false,"given":"Clifford","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-0573","authenticated-orcid":false,"given":"Phyu P.","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8370-1432","authenticated-orcid":false,"given":"Lawrence N.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janos","family":"Roszik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-7721","authenticated-orcid":false,"given":"Rehan","family":"Akbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kossenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8124-0900","authenticated-orcid":false,"given":"Vito W.","family":"Rebecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-0739","authenticated-orcid":false,"given":"Meenhard","family":"Herlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-0912","authenticated-orcid":false,"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"74691_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954 (2002).","journal-title":"Nature"},{"key":"74691_CR2","doi-asserted-by":"publisher","unstructured":"Genomic Classification of Cutaneous Melanoma. Cell 161, 1681-1696 https:\/\/doi.org\/10.1016\/j.cell.2015.05.044 (2015).","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"74691_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74691_CR4","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long, G. V. et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 17, 1743\u20131754 (2016).","journal-title":"Lancet Oncol."},{"key":"74691_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","volume":"82","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf, D. et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur. J. Cancer 82, 45\u201355 (2017).","journal-title":"Eur. J. Cancer"},{"key":"74691_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002\u20131014 (2021).","journal-title":"Lancet"},{"key":"74691_CR7","doi-asserted-by":"publisher","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1910836 (2019).","DOI":"10.1056\/NEJMoa1910836"},{"key":"74691_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto, P. A. et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J. Clin. Oncol. 41, 212\u2013221 (2023).","journal-title":"J. Clin. Oncol."},{"key":"74691_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.48","volume":"1","author":"CC Jiang","year":"2010","unstructured":"Jiang, C. C. et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 1, e69 (2010).","journal-title":"Cell Death Dis."},{"key":"74691_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/2159-8290.CD-11-0106","volume":"1","author":"AC Faber","year":"2011","unstructured":"Faber, A. C. et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 1, 352\u2013365 (2011).","journal-title":"Cancer Discov."},{"key":"74691_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nm.2713","volume":"18","author":"KP Ng","year":"2012","unstructured":"Ng, K. P. et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 18, 521\u2013528 (2012).","journal-title":"Nat. Med"},{"key":"74691_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/1535-7163.MCT-09-0651","volume":"9","author":"SK Tahir","year":"2010","unstructured":"Tahir, S. K. et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia\/lymphoma cell lines. Mol. Cancer Ther. 9, 545\u2013557 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"74691_CR13","doi-asserted-by":"publisher","first-page":"e101286","DOI":"10.1371\/journal.pone.0101286","volume":"9","author":"DT Frederick","year":"2014","unstructured":"Frederick, D. T. et al. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One 9, e101286 (2014).","journal-title":"PLoS One"},{"key":"74691_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat, V. A. et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 11, 1440\u20131453 (2021).","journal-title":"Cancer Discov."},{"key":"74691_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.178","volume":"3","author":"S Ackler","year":"2015","unstructured":"Ackler, S. et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharm. Res Perspect. 3, e00178 (2015).","journal-title":"Pharm. Res Perspect."},{"key":"74691_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","volume":"15","author":"TE Lew","year":"2022","unstructured":"Lew, T. E. & Seymour, J. F. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. J. Hematol. Oncol. 15, 75 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"74691_CR17","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1158\/0008-5472.CAN-23-2804","volume":"83","author":"A Skwarska","year":"2023","unstructured":"Skwarska, A. & Konopleva, M. BCL-xL targeting to induce apoptosis and to eliminate chemotherapy-induced senescent tumor cells: from navitoclax to platelet-sparing BCL-xL PROTACs. Cancer Res 83, 3501\u20133503 (2023).","journal-title":"Cancer Res"},{"key":"74691_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05963-1","volume":"14","author":"E Valentini","year":"2023","unstructured":"Valentini, E. et al. Bcl-2 family inhibitors sensitize human cancer models to therapy. Cell Death Dis. 14, 441 (2023).","journal-title":"Cell Death Dis."},{"key":"74691_CR19","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","volume":"25","author":"I Ploumaki","year":"2023","unstructured":"Ploumaki, I. et al. Bcl-2 pathway inhibition in solid tumors: a review of clinical trials. Clin. Transl. Oncol. 25, 1554\u20131578 (2023).","journal-title":"Clin. Transl. Oncol."},{"key":"74691_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.canlet.2020.11.036","volume":"499","author":"ML Hartman","year":"2021","unstructured":"Hartman, M. L., Gajos-Michniewicz, A., Talaj, J. A., Mielczarek-Lewandowska, A. & Czyz, M. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF(V600E) melanoma cells. Cancer Lett. 499, 122\u2013136 (2021).","journal-title":"Cancer Lett."},{"key":"74691_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12409-w","volume":"10","author":"MJ Sale","year":"2019","unstructured":"Sale, M. J. et al. Targeting melanoma\u2019s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1\/2 pathway inhibitors. Nat. Commun. 10, 5167 (2019).","journal-title":"Nat. Commun."},{"key":"74691_CR22","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1172\/JCI35437","volume":"118","author":"MS Cragg","year":"2008","unstructured":"Cragg, M. S. et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest 118, 3651\u20133659 (2008).","journal-title":"J. Clin. Invest"},{"key":"74691_CR23","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.celrep.2017.10.021","volume":"21","author":"C Krepler","year":"2017","unstructured":"Krepler, C. et al. A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma. Cell Rep. 21, 1953\u20131967 (2017).","journal-title":"Cell Rep."},{"key":"74691_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41588-020-00750-6","volume":"53","author":"XY Woo","year":"2021","unstructured":"Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet 53, 86\u201399 (2021).","journal-title":"Nat. Genet"},{"key":"74691_CR25","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1073\/pnas.1205575110","volume":"110","author":"R Haq","year":"2013","unstructured":"Haq, R. et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc. Natl. Acad. Sci. USA 110, 4321\u20134326 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74691_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1535-7163.MCT-23-0471","volume":"23","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Assessment of patient-derived xenograft growth and antitumor activity: the NCI PDXNet consensus recommendations. Mol. Cancer Ther. 23, 924\u2013938 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"74691_CR27","volume":"44","author":"MA Mansour","year":"2025","unstructured":"Mansour, M. A., El-Salamoni, M. A. & Mostafa, H. N. Harnessing PUMA\u2019s lethal potential: BCL-2 family dynamics and novel strategies to combat cancer recurrence. Cancer Treat. Res. Commun. 44, 100975 (2025).","journal-title":"Cancer Treat. Res. Commun."},{"key":"74691_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4887","volume":"5","author":"R Akbani","year":"2014","unstructured":"Akbani, R. et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887 (2014).","journal-title":"Nat. Commun."},{"key":"74691_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med"},{"key":"74691_CR30","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"74691_CR31","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00262-020-02804-4","volume":"70","author":"L Peiffer","year":"2021","unstructured":"Peiffer, L. et al. BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes. Cancer Immunol. Immunother. 70, 1635\u20131647 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"74691_CR32","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","volume":"3","author":"I de Weerdt","year":"2019","unstructured":"de Weerdt, I. et al. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv. 3, 2642\u20132652 (2019).","journal-title":"Blood Adv."},{"key":"74691_CR33","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1158\/2159-8290.CD-22-1338","volume":"13","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 13, 2448\u20132469 (2023).","journal-title":"Cancer Discov."},{"key":"74691_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp, F. J. et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 11, 68\u201379 (2021).","journal-title":"Cancer Discov."},{"key":"74691_CR35","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1038\/s41409-021-01245-6","volume":"56","author":"L Siblany","year":"2021","unstructured":"Siblany, L. et al. Venetoclax does not impair activated T-cell proliferation. Bone Marrow Transpl. 56, 1740\u20131742 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"74691_CR36","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1200\/JCO.2023.41.16_suppl.9511","volume":"41","author":"Z Eroglu","year":"2023","unstructured":"Eroglu, Z. et al. Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466). J. Clin. Oncol. 41, 9511\u20139511 (2023).","journal-title":"J. Clin. Oncol."},{"key":"74691_CR37","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey, H. E. et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 8, 1566\u20131581 (2018).","journal-title":"Cancer Discov."},{"key":"74691_CR38","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","volume":"25","author":"D Prukova","year":"2019","unstructured":"Prukova, D. et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin. Cancer Res. 25, 4455\u20134465 (2019).","journal-title":"Clin. Cancer Res."},{"key":"74691_CR39","doi-asserted-by":"publisher","first-page":"46801","DOI":"10.18632\/oncotarget.8695","volume":"8","author":"N Mukherjee","year":"2017","unstructured":"Mukherjee, N. et al. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget 8, 46801\u201346817 (2017).","journal-title":"Oncotarget"},{"key":"74691_CR40","doi-asserted-by":"publisher","first-page":"40535","DOI":"10.18632\/oncotarget.5755","volume":"6","author":"NM Fofaria","year":"2015","unstructured":"Fofaria, N. M., Frederick, D. T., Sullivan, R. J., Flaherty, K. T. & Srivastava, S. K. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1\/2 inhibitors in melanoma. Oncotarget 6, 40535\u201340556 (2015).","journal-title":"Oncotarget"},{"key":"74691_CR41","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1101\/gad.215855.113","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 27, 1351\u20131364 (2013).","journal-title":"Genes Dev."},{"key":"74691_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101015","volume":"23","author":"ML Rasmussen","year":"2020","unstructured":"Rasmussen, M. L. et al. MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. iScience 23, 101015 (2020).","journal-title":"iScience"},{"key":"74691_CR43","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-14-1392","volume":"74","author":"YNV Gopal","year":"2014","unstructured":"Gopal, Y. N. V. et al. Inhibition of mTORC1\/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1\u03b1 and oxidative phosphorylation in melanoma. Cancer Res. 74, 7037\u20137047 (2014).","journal-title":"Cancer Res."},{"key":"74691_CR44","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1158\/1078-0432.CCR-19-0836","volume":"25","author":"YN Vashisht Gopal","year":"2019","unstructured":"Vashisht Gopal, Y. N. et al. A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma. Clin. Cancer Res. 25, 6429\u20136442 (2019).","journal-title":"Clin. Cancer Res."},{"key":"74691_CR45","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23, 302\u2013315 (2013).","journal-title":"Cancer Cell"},{"key":"74691_CR46","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488\u2013496 (2012).","journal-title":"J. Clin. Oncol."},{"key":"74691_CR47","doi-asserted-by":"publisher","first-page":"7145","DOI":"10.1182\/blood-2011-03-344812","volume":"117","author":"M Vogler","year":"2011","unstructured":"Vogler, M. et al. BCL2\/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 117, 7145\u20137154 (2011).","journal-title":"Blood"},{"key":"74691_CR48","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","volume":"9","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju, N. et al. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol. 9, e434\u2013e444 (2022).","journal-title":"Lancet Haematol."},{"key":"74691_CR49","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877\u20131888 (2014).","journal-title":"N. Engl. J. Med"},{"key":"74691_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/0284186X.2021.1992010","volume":"61","author":"S Pedersen","year":"2022","unstructured":"Pedersen, S. et al. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. Acta Oncol. 61, 45\u201351 (2022).","journal-title":"Acta Oncol."},{"key":"74691_CR51","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.molcel.2024.02.035","volume":"84","author":"T Wright","year":"2024","unstructured":"Wright, T. et al. Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. Mol. Cell 84, 1338\u20131353.e1338 (2024).","journal-title":"Mol. Cell"},{"key":"74691_CR52","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado, J. et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin. Cancer Res. 26, 922\u2013934 (2020).","journal-title":"Clin. Cancer Res."},{"key":"74691_CR53","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/leu.2015.10","volume":"29","author":"GP Gregory","year":"2015","unstructured":"Gregory, G. P. et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia 29, 1437\u20131441 (2015).","journal-title":"Leukemia"},{"key":"74691_CR54","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1200\/JCO.2024.42.16_suppl.3102","volume":"42","author":"MA Villalona-Calero","year":"2024","unstructured":"Villalona-Calero, M. A. et al. Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors. J. Clin. Oncol. 42, 3102\u20133102 (2024).","journal-title":"J. Clin. Oncol."},{"key":"74691_CR55","doi-asserted-by":"crossref","unstructured":"Strati, P. et al. P1126: Phase 1b\/2a Study Of Azd4573 (Cdk9i) And Acalabrutinib In Patients (Pts) With Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (R\/R Dlbcl). Hemasphere 7, e47925e9 (2023).","DOI":"10.1097\/01.HS9.0000971400.47925.e9"},{"key":"74691_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee, J. B. et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood 138, 234\u2013245 (2021).","journal-title":"Blood"},{"key":"74691_CR57","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.celrep.2017.10.052","volume":"21","author":"B Garman","year":"2017","unstructured":"Garman, B. et al. Genetic and genomic characterization of 462 melanoma patient-derived xenografts, tumor biopsies, and cell lines. Cell Rep. 21, 1936\u20131952 (2017).","journal-title":"Cell Rep."},{"key":"74691_CR58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/1078-0432.CCR-22-2661","volume":"29","author":"AW Hahn","year":"2023","unstructured":"Hahn, A. W. et al. Obesity is associated with altered tumor metabolism in metastatic melanoma. Clin. Cancer Res. 29, 154\u2013164 (2023).","journal-title":"Clin. Cancer Res"},{"key":"74691_CR59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202\u2013216 (2016).","journal-title":"Cancer Discov."},{"key":"74691_CR60","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1515\/hsz-2016-0107","volume":"397","author":"J Ryan","year":"2016","unstructured":"Ryan, J., Montero, J., Rocco, J. & Letai, A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol. Chem. 397, 671\u2013678 (2016).","journal-title":"Biol. Chem."},{"key":"74691_CR61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-4939-8861-7_4","volume":"1877","author":"C Fraser","year":"2019","unstructured":"Fraser, C., Ryan, J. & Sarosiek, K. BH3 profiling: a functional assay to measure apoptotic priming and dependencies. Methods Mol. Biol. 1877, 61\u201376 (2019).","journal-title":"Methods Mol. Biol."},{"key":"74691_CR62","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","volume":"9","author":"GM Fischer","year":"2019","unstructured":"Fischer, G. M. et al. Molecular profiling reveals unique immune and metabolic feature of melanoma brain metastases. Cancer Discov. 9, 628\u2013645 (2019).","journal-title":"Cancer Discov."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74691-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74691-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74691-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:18:16Z","timestamp":1785521896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74691-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74691"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74691-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.D. has been a consultant to Replimmune, Nurix, Roche\/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics; he is a scientific advisory board member for THERAtRAME; and he has been the PI of research grants to MD Anderson by Roche\/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. M.A.D. is supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH\/NCI P50CA221703, the American Cancer Society and the Melanoma Research Alliance, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research, the Andrew M. McDougall Brain Metastasis Clinic and Research Program, and philanthropic contributions to the MD Anderson Melanoma Moon Shots Program. YNVG previously received grant funding from Melanoma Research Alliance and Calithera Biosciences. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7582"}}